The core problem: why biologics need a scaffold to work

Stem cells injected freely into a joint rarely stay where they're needed. Synovial fluid — the natural lubricant that bathes the knee — turns over continuously, and any liquid biologic placed into that environment is washed away from the defect site within hours of injection. For a focused focal cartilage lesion, this is the central problem: the biological payload arrives but cannot anchor long enough to do its work.

ChondroFiller® is an acellular injectable Type I collagen scaffold, CE Class III–designated and manufactured by Meidrix Biomedicals. Delivered as a liquid under ultrasound guidance, it self-gels within minutes of placement, conforming precisely to the contours of a focal defect. That transition from liquid to structured gel is the key step: it converts the treatment zone from an open, fluid-flushed space into a stable three-dimensional matrix.

When bone marrow aspirate concentrate (BMAC) — a cell-rich preparation drawn from the patient's own marrow — is co-delivered into that setting gel, the scaffold physically holds the MSC-containing concentrate in place. The washout problem is addressed not by changing the biology, but by changing the environment.

This combination is designed for a specific clinical situation: a focal cartilage defect in which the patient's endogenous cell supply is unlikely to be sufficient on its own. It is not a blanket treatment for widespread osteoarthritis.

How the collagen scaffold gels and holds cells in place

Two syringes, one reaction. ChondroFiller® Liquid arrives as a two-component system; when the collagen precursors meet at the point of injection, they initiate a cross-linking reaction that sets the matrix within minutes. The resulting gel fills the defect contour precisely — irregular borders, sloped edges, and all — without requiring any shaping by the clinician.

What makes that gel functionally useful as a retention matrix is its internal architecture. Rather than forming a solid plug, the collagen sets into a three-dimensional network of interconnected microscopic channels. These pores serve three simultaneous purposes: cells can migrate inward through them; nutrients can reach cells that have settled in the deeper zones; and metabolic waste products can clear outward. Think of it as a sponge that holds its contents while remaining permeable — form and function arising from the same structural feature. Experimental work in highly porous (99% porosity) interconnected collagen architectures has demonstrated enhanced sulphated glycosaminoglycan distribution and early cartilaginous matrix deposition by MSCs, confirming that it is the pore network, not merely the collagen chemistry, that drives retention and tissue formation.

For the BMAC component, this architecture matters directly. The MSC-rich and platelet-rich concentrate is co-delivered into the setting gel; as the scaffold solidifies around it, the pores physically anchor those cells in place. The containment mechanism is structural rather than chemical.

ChondroFiller itself contains no cells — it is deliberately acellular. The scaffold's role is to provide a structural host for progenitor cells, whether those arrive via co-delivered BMAC or migrate in from the surrounding synovium and subchondral bone. Cell supply and scaffold structure are separate contributions.

What BMAC adds: concentrated MSCs and chondrogenic signals

A small volume of bone marrow — typically drawn from the iliac crest — is the starting point. In the same outpatient appointment, that aspirate is placed into a centrifuge and spun to separate and concentrate the biologically active fractions. The resulting BMAC is markedly richer than the original marrow: centrifuge processing significantly enriches MSC subpopulations including CD45−CD73+ and CD45dimCD271+ populations, alongside platelets and chondrogenic growth factors — notably PDGF and VEGF. Cell viability after processing is approximately 90%, meaning the concentrate loaded into the collagen scaffold remains biologically active at the point of injection.

That enrichment step matters in practice because unprocessed marrow aspirate contains MSCs only in modest and highly variable numbers. Concentration by centrifugation converts a limited harvest into a focused, cell-dense preparation — one that, retained within the setting ChondroFiller scaffold, sustains the biological activity the repair process depends on.

ChondroFiller also recruits cells independently: its collagen matrix releases chemotactic signals that draw native MSCs from surrounding synovium and subchondral bone into the scaffold. For patients with healthy, well-vascularised subchondral tissue and a small defect, that endogenous supply may prove adequate. The rationale for adding BMAC becomes most compelling where this assumption weakens — in older patients, in larger defects, or where the subchondral marrow is depleted. The 2025 prospective controlled trial examining the ChondroFiller Liquid and BMAC combination enrolled patients with grade IV knee osteoarthritis, a clinical context in which local progenitor-cell supply cannot be assumed; this suggests the exogenous BMAC bolus has greatest clinical purpose precisely where endogenous reserves are in question, rather than as a universal addition to every scaffold implantation.

The scaffold as a chondrogenic cue, not a passive carrier

Physical structure alone does not determine whether a scaffold produces cartilage-like tissue. The mechanical properties of the collagen gel — specifically its stiffness and the rate at which it deforms and recovers under load — function as direct biological signals, shaping what the captured stem cells go on to produce.

Research into collagen hydrogel viscoelasticity shows that how quickly the gel relaxes around cells is a direct determinant of MSC fate. Faster-relaxing collagen hydrogels promote cell-matrix adhesion and sustain chondrogenesis over time, acting through the ROCK signalling pathway; slower-relaxing gels activate the same pathway in a way that causes MSC apoptosis rather than differentiation. The gel's physical character — how readily it yields and recovers — steers stem cells toward cartilage production or away from it.

Stiffness contributes independently. Three-dimensional collagen constructs calibrated to approximately 5.75 kPa have been shown to drive MSC differentiation toward collagen type II and aggrecan synthesis — the proteins characteristic of hyaline rather than fibrocartilage — without any exogenous growth factors. The matrix itself provides the instructive signal; no additional chemical prompts are required.

This is what separates ChondroFiller from a permanent space-occupying hydrogel such as Arthrosamid (polyacrylamide). Arthrosamid remains in the joint indefinitely and is not regenerative — it does not engage MSC biology or direct tissue formation. ChondroFiller, by contrast, is a temporary scaffold whose material properties actively participate in steering repair toward hyaline-like cartilage before the matrix is gradually resorbed. One occupies space; the other works with the cell biology already present in the joint.

Protecting subchondral bone — the case against microfracture

Beneath cartilage lies a layer of dense bone — the subchondral plate — whose mechanical function is inseparable from the long-term health of the joint surface above it. Microfracture, one of the longest-established cartilage repair techniques, works by deliberately perforating this plate with an awl to release bone-marrow cells into the defect. The approach is technically simple, but the breach it creates carries a recognised cost: altering the subchondral architecture can affect the biomechanical loading of the repair site, a limitation that becomes more consequential in defects larger than approximately 4 cm².

The tissue that fills a microfracture-treated defect also tends toward fibrocartilage rather than hyaline-like cartilage — less durable under repeated joint loading — partly because the cellular environment released by subchondral drilling is not ideally suited to directing chondrogenesis at the joint surface.

When ChondroFiller is combined with BMAC, the need to drill the subchondral plate disappears. BMAC provides the concentrated MSC supply from a separate harvest site, and the collagen scaffold retains those cells within the defect as it sets. The intact subchondral plate continues to support the repair from below, while the scaffold stabilises any intralesional clot that forms and encourages differentiation along a chondrogenic rather than fibrogenic path. Preserving the subchondral bone in this way carries particular weight where the tissue beneath a focal lesion is already under mechanical stress — a context that is directly relevant in higher-grade focal defects where long-term joint function depends on what lies beneath the repair as much as the repair tissue itself.

Clinical outcomes and what the evidence currently shows

Published data across more than 19,000 ChondroFiller cases globally provide a substantive foundation: multi-centre studies report approximately 30-point IKDC score improvements in knee patients, MOCART MRI scores of 70–87, and a complaint rate of around 0.06%. A 2024 knee-specific study of 17 patients (mean age 31) found statistically significant Lysholm and IKDC gains at 3, 6, and 12 months post-treatment, with scores plateauing between the six- and twelve-month timepoints — broadly consistent with the 6–12 month window in which new cartilage matrix is typically deposited.

The evidence specifically for the ChondroFiller Liquid + BMAC combination is narrower. A 2025 prospective controlled trial examined this pairing as a joint-preservation strategy in patients with grade IV knee osteoarthritis — the most direct published evidence for the combination rather than for the scaffold alone. That single trial moves the combination beyond biological rationale into clinical corroboration, but it has not yet been replicated at scale or across multiple centres.

The remaining gap is histological: the proportion of hyaline-like versus fibrocartilage tissue generated specifically by the ChondroFiller + BMAC combination has not been established by long-term biopsy data. The wider collagen scaffold and MSC chondrogenesis literature supports the biological case for hyaline-like repair, but evidence from mechanistically analogous work is not confirmation drawn from this specific combination.

On current evidence, the pairing sits at a promising-and-rationale-supported stage: a scaffold with a large real-world track record, one prospective combination trial, and a coherent mechanistic basis — but not yet the multi-centre corroboration with histological follow-up that would settle the tissue-quality question definitively. Whether this pathway is appropriate for an individual patient depends on defect size and grade, symptom trajectory, and imaging findings — factors that require a specialist cartilage assessment rather than general eligibility criteria.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Collagen hydrogel viscoelasticity regulates MSC chondrogenesis in a ROCK-dependent manner. (2023). https://doi.org/10.1126/sciadv.ade9497 https://doi.org/10.1126/sciadv.ade9497
3. [3] Soft substrates direct stem cell differentiation into the chondrogenic lineage without the use of growth factors. (2022). https://doi.org/10.1177/20417314221122121 https://doi.org/10.1177/20417314221122121
4. [4] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft - A Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360